Discovery of AB680: A Potent and Selective Inhibitor of CD73
- 2 July 2020
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 63 (20) , 11448-11468
Abstract
Extracellular adenosine (ADO), present in high concentrations in the tumor microenvironment (TME), suppresses immune function via inhibition of T cell and NK cell activation. Intratumoral generation of ADO depends on the sequential catabolism of ATP by two ecto-nucleotidases, CD39 (ATP → AMP) and CD73 (AMP → ADO). Inhibition of CD73 eliminates a major pathway of ADO production in the TME and can reverse ADO-mediated immune suppression. Extensive interrogation of structure–activity relationships (SARs), structure-based drug design, and optimization of pharmacokinetic properties culminated in the discovery of AB680, a highly potent (Ki = 5 pM), reversible, and selective inhibitor of CD73. AB680 is further characterized by very low clearance and long half-lives across preclinical species, resulting in a PK profile suitable for long-acting parenteral administration. AB680 is currently being evaluated in phase 1 clinical trials. Initial data show AB680 is well tolerated and exhibits a pharmacokinetic profile suitable for biweekly (Q2W) iv-administration in human.Keywords
This publication has 38 references indexed in Scilit:
- Tumour-intrinsic resistance to immune checkpoint blockadeNature Reviews Immunology, 2019
- Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshopJournal for ImmunoTherapy of Cancer, 2019
- The future of immune checkpoint therapyScience, 2015
- Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative PotentialCell, 2015
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 TherapyClinical Cancer Research, 2014
- A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical applicationNature Immunology, 2013
- CD39 and CD73 in immunity and inflammationTrends in Molecular Medicine, 2013
- Extracellular adenosine triphosphate and adenosine in cancerOncogene, 2010
- Ecto-5’-nucleotidase: Structure function relationshipsPurinergic Signalling, 2006
- 5′-Nucleotidase: molecular structure and functional aspectsBiochemical Journal, 1992